Incidence and predictors of anthracycline-related left ventricular dysfunction in acute myeloid leukemia
- 12 July 2023
- journal article
- research article
- Published by Elsevier in Leukemia Research
- Vol. 132, 107351
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Validation and Implementation of a Custom Next-Generation Sequencing Clinical Assay for Hematologic MalignanciesThe Journal of Molecular Diagnostics, 2016
- Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure TherapyCirculation, 2015
- Age-Related Clonal Hematopoiesis Associated with Adverse OutcomesNew England Journal of Medicine, 2014
- Cardiac hypertrophy associated with myeloproliferative neoplasms in JAK2V617F transgenic miceJournal of Hematology & Oncology, 2014
- Anthracyclines and Heart FailureNew England Journal of Medicine, 2013
- Anthracycline Dose Intensification in Acute Myeloid LeukemiaNew England Journal of Medicine, 2009
- High risk of cardiac dysfunction after treatment of secondary acute myeloid leukaemia to breast cancerAnnals of Oncology, 2009
- The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia.British Journal of Haematology, 2007
- Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCTBlood, 2005
- Congestive heart failure in patients treated with doxorubicinCancer, 2003